A61P1/16

APPLICATION OF CST1 IN PREVENTION AND/OR TREATMENT OF LIVER IMMUNE DYSREGULATION DISEASES

The present invention provides an application of CST1 in prevention and/or treatment of liver immune dysregulation diseases. Specifically, the present invention provides an application of a CST1 gene, or a protein thereof, or a promoter thereof for preparing a composition or a preparation. The composition or the preparation is used for prevention and/or treatment of liver immune dysregulation diseases.

METHODS OF TREATING LYMPHEDEMA WITH DEUPIRFENIDONE
20230040415 · 2023-02-09 ·

Disclosed herein are methods of treating lymphedema that include administering a clinically effective amount of deupirfenidone.

METHODS OF TREATING LYMPHEDEMA WITH DEUPIRFENIDONE
20230040415 · 2023-02-09 ·

Disclosed herein are methods of treating lymphedema that include administering a clinically effective amount of deupirfenidone.

COMPOSITIONS AND METHODS FOR INHIBITING MITOCHONDRIA AMIDOXIME REDUCING COMPONENT 1 (MARC1) EXPRESSION

Oligonucleotides are provided herein that inhibit MARC1 expression. Also provided are compositions including the same and uses thereof, particularly uses relating to treating diseases, disorders and/or conditions associated with MARC1 expression.

COMPOSITIONS AND METHODS FOR INHIBITING MITOCHONDRIA AMIDOXIME REDUCING COMPONENT 1 (MARC1) EXPRESSION

Oligonucleotides are provided herein that inhibit MARC1 expression. Also provided are compositions including the same and uses thereof, particularly uses relating to treating diseases, disorders and/or conditions associated with MARC1 expression.

USE OF TERPENOIDS IN THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES
20230041859 · 2023-02-09 ·

The present invention relates to a method of preventing or treating a fibrotic condition, comprising administering an effective amount of composition to a subject in need thereof; wherein the composition comprises triterpenes extracted from Antrodia camphorate or Anisomeles indica.

USE OF TERPENOIDS IN THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES
20230041859 · 2023-02-09 ·

The present invention relates to a method of preventing or treating a fibrotic condition, comprising administering an effective amount of composition to a subject in need thereof; wherein the composition comprises triterpenes extracted from Antrodia camphorate or Anisomeles indica.

Bile acid synthesis promoter, composition for promoting bile acid synthesis and food composition for promoting bile acid synthesis

[Problem] To provide a novel medicine that is capable of promoting cholesterol metabolism to thereby treat, ameliorate or prevent various symptoms associated with increase in blood cholesterol level. [Solution] The present inventors newly found that arctigenin has an effect of promoting the conversion of cholesterol into bile acid. The present invention provides a bile acid synthesis promoter, a composition for promoting bile acid synthesis and a food composition for promoting bile acid synthesis each comprising arctigenin and/or arctiin as active ingredient(s).

Bile acid synthesis promoter, composition for promoting bile acid synthesis and food composition for promoting bile acid synthesis

[Problem] To provide a novel medicine that is capable of promoting cholesterol metabolism to thereby treat, ameliorate or prevent various symptoms associated with increase in blood cholesterol level. [Solution] The present inventors newly found that arctigenin has an effect of promoting the conversion of cholesterol into bile acid. The present invention provides a bile acid synthesis promoter, a composition for promoting bile acid synthesis and a food composition for promoting bile acid synthesis each comprising arctigenin and/or arctiin as active ingredient(s).

Purine diones as Wnt pathway modulators

The invention relates to the use of compounds of general structure (I) in modulation of the Wnt pathway ##STR00001##
wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are each, independently, H or an alkyl group; D is selected from the group consisting of H, halogen, alkyl, cycloalkyl, aryl, and dialkylamino, each (other than H and halogen) being optionally substituted; Ar is an aryl or heteroaryl group, optionally substituted; Cy is an aryl, heteroaryl or a saturated ring containing at least one heteroatom, each being optionally substituted; and n is an integer from 1 to 3.